NasdaqGS:BCRXBiotechs
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case
BioCryst Pharmaceuticals (NasdaqGS:BCRX) has granted Neopharmed Gentili exclusive European licensing rights to navenibart for hereditary angioedema.
The agreement includes an upfront payment and potential future milestone payments to BioCryst.
Neopharmed Gentili is expected to use its existing European commercial infrastructure to support the rollout of navenibart.
At ISPOR 2026, BioCryst presented real world evidence on pediatric hereditary angioedema highlighting ongoing medical and...